US drug major Eli Lilly (NYSE: LLY) says that the US Food and Drug Administration’s Gastrointestinal Drugs Advisory Committee has voted by nine to three that clinical data submitted to support the New Drug Application for approval of Solpura (liprotamase) did not provide "substantial evidence of the efficacy" and voted not to recommend approval of the drug, a non-porcine pancreatic enzyme replacement therapy (PERT), currently under the agency’s review for the treatment of exocrine pancreatic insufficiency (EPI), such as cystic fibrosis.
During the meeting, the committee had questions about the degree of efficacy of liprotamase and recommended that additional studies be conducted prior to considering approval of liprotamase for EPI. The drug is being developed by Lilly’s wholly-owned subsidiary Alnara Pharmaceuticals, which it acquired for an undisclosed sum last year, though reportedly this was around $380 million (The Pharma Letter July 5. 2010)
"We appreciate the feedback the committee has provided, and we will continue to work with the FDA to address the questions raised in the meeting as the agency moves toward a final decision on the application," said Eiry Roberts, vice president, autoimmune, bone-muscle-joint, liprotamase product development, at Lilly, adding: "We remain confident in the clinical trial data package submitted to the FDA in support of the liprotamase application."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze